GlassScriptPhysician profile
Neha P Rickson
NPI 1568657732
$8,135.48
in general payments reported to CMS, 2019-2025
40 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,672 · 2020: $2,959 · 2021: $106 · 2022: $113 · 2023: $199 · 2024: $499 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.91 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $5,027.25 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $347.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $333.84 | 2019-2025 | Mounjaro, Jardiance |
| Ibsa Pharma INC. | $227.77 | 2020-2025 | Tirosint, Licart, Flector |
| Abbvie INC. | $226.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $171.01 | 2019-2020 | |
| Radius Health, INC. | $147.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $129.78 | 2019-2020 | |
| Amgen INC. | $121.12 | 2019-2025 | Evenity, Repatha |
| Recordati_rare_diseases_inc. | $109.19 | 2021-2025 | Isturisa |
| Amneal Pharmaceuticals LLC | $105.77 | 2019-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.71 | 2019 | |
| Shire North American Group INC | $93.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.63 | 2019-2020 | |
| Amarin Pharma, INC. | $74.96 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Rickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.